6,514.50
+2.21%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Astrazeneca Pharma India
Its shares trade on NSE under the ticker ASTRAZEN.NS. It has been listed since 30 July 1998. In the fiscal year to 31 March 2025, it reported revenue of ₹17.16bn and net income of ₹1.16bn. At that date it held total assets of ₹15.18bn and shareholders' equity of ₹7.70bn.
AstraZeneca Pharma India Ltd. is engaged in the manufacture, distribution, and marketing of pharmaceutical products and clinical trial services. The company is headquartered in Bangalore, Karnataka. Its therapeutic areas include cardiovascular, renal and metabolism; oncology, and respiratory diseases. The firm operates through Healthcare segment. The firm is engaged in the business of manufacturing, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The firm has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Company’s DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 30 Jul 1998
- Employees
- 947
- Website
- astrazeneca.in ↗
Leadership
Pay as last reported
- Ms. Shilpa NirulaChairperson of the Board, since 2021₹1.3m
- Mrs. Bhavana AgrawalChief Financial Officer, Whole-time Director, since 2023₹4.6m
- Ms. Manasa RamaCompliance Officer, Company Secretary
- Dr. Sanjeev PanchalManaging Director, Executive Director, since 2023₹38.7m
- Ms. Hooi-Bien ChuahNon-Executive Director
- Mr. Jesus Javier EstesoNon-Executive Director
- Ms. Sylvia Lorena Varela RamonNon-Executive Director
- Ms. Monica WidhaniIndependent Director
- Ms. Revathy AshokNon-Executive Independent Director₹1.2m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 83
- Environment
- 99
- Social
- 75
- Governance
- 76
- Direct emissions (scope 1)
- 452 t
- Energy emissions (scope 2)
- 0 t
- Women in the workforce
- 19.89%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Bangalore with 947 employees
- Offers therapeutic areas including cardiovascular, renal, metabolism, oncology, and respiratory diseases
- Provides clinical trial services to an overseas group company
Weaknesses
- No specific weaknesses mentioned in the provided information
- No details on financial performance or market share provided
- No information on competitive disadvantages or operational challenges
Opportunities
- Expansion in therapeutic areas such as cardiovascular, renal, and metabolism
- Growth potential in oncology business with approved drugs like Imfinzi and Lynparza
- Portfolio expansion in oral antidiabetic drugs with SGLT2 and DPP4 inhibitors
Threats
- No specific threats mentioned in the provided information
- No details on regulatory challenges or market competition provided
- No information on potential risks to business operations
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.